[1] RIZVI S, GORES G J. Pathogenesis, diagnosis, and management of cholangiocarcinoma [J]. Gastroenterology, 2013, 145(6):1215-1229.
[2] MISRA S, CHATURVEDI A, MISRA N C, et al. Carcinoma of the gallbladder [J]. Lancet Oncol, 2003, 4(3):167-176.
[3] KHAN S A, THOMAS H C, DAVIDSON B R, et al. Cholangiocarcinoma [J]. Lancet, 2005, 366(9493):1303-1314.
[4] BUONACERA A, STANCANELLI B, COLACI M, et al. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases[J]. Int J Mol Sci, 2022, 23(7):3636.
[5] YUN J, CHUNG M, BAEK C, et al. Prognostic significance of the post-treatment neutrophil-to-lymphocyte ratio in pharyngeal cancers treated with concurrent chemoradiotherapy [J].Cancers: Basel, 2023, 15(4):1248.
[6] LI Q, KONG F, MA J, et al. Nomograms based on fibrinogen, albumin, neutrophil-lymphocyte ratio, and carbohydrate antigen 125 for predicting endometrial cancer prognosis [J].Cancers: Basel, 2022, 14(22):5632.
[7] SUN X, SUN Z, ZHU Z, et al. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients [J]. PLoS One, 2014, 9(3):e91068.
[8] KOUKOURAKIS M I, GIATROMANOLAKI A, PANTELIADOU M, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy [J]. Br J Cancer, 2014, 110(9):2217-2223.
[9] LIU X, MENG Q H, YE Y, et al. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer [J]. Carcinogenesis, 2015, 36(2):243-248.
[10] HAAS M, HEINEMANN V, KULLMANN F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy [J]. J Cancer Res Clin Oncol, 2013, 139(4):681-689. |
